Conceptual and analytical considerations toward the use of patient-reported outcomes in personalized medicine

American Health and Drug Benefits

Volumn 5, Issue 5, 2012, Pages

  Alemayehu, Demissie ^a   Cappelleri, Joseph C ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ANALYTICAL PARAMETERS; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONCEPTUAL FRAMEWORK; DATA ANALYSIS; FOLLOW UP; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GOLD STANDARD; HEALTH CARE DELIVERY; HEALTH CARE MANAGEMENT; HEALTH CARE NEED; HEALTH CARE UTILIZATION; INSTRUMENT VALIDATION; LONGITUDINAL STUDY; MACHINE LEARNING; MEDICAL INFORMATION; MEDICAL PARAMETERS; MEDICAL RESEARCH; PATIENT CARE; PATIENT REPORTED OUTCOME; PATIENT SELECTION; PERSONALIZED MEDICINE; PROCESS DEVELOPMENT; PROCESS MODEL; RISK BENEFIT ANALYSIS; STATISTICAL ANALYSIS; STUDY DESIGN; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84865515969     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Sprangers MA, Sloan JA, Barsevick A, et al. Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes. Qual Life Res. 2010;19:1395-1403.
2. Shi Q, Cleeland CS, Klepstad P, et al. Biological pathways and genetic variables involved in pain. Qual Life Res. 2010;19:1407-1417.
3. Raat H, van Rossem L, Jaddoe VW, et al. The Generation R study: a candidate gene study and genome-wide association study (GWAS) on health-related quality of life (HRQOL) of mothers and young children. Qual Life Res. 2010;19:1439-1446.
4. Rijsdijk FV, Snieder H, Ormel J, et al. Genetic and environmental influences on psychological distress in the population: General Health Questionnaire analysis in UK twins. Psychol Med. 2003;33:793-801.
5. Leinonen R, Kaprio J, Jylhä M, et al. Genetic influences underlying self-rated health in older female twins. J Am Geriatr Soc. 2005;53:1002-1007.
6. Romeis JC, Scherrer JF, Xian H, et al. Heritability of self-reported health. Health Serv Res. 2000;35:995-1010.
7. Yang P, Mandrekar SJ, Hillman SH, et al. Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based study. J Thorac Oncol. 2009;4:479-485.
8. Sloan JA, Dueck AC, Erickson PA, et al. Analysis and interpretation of results based on patientreported outcomes. Value Health. 2007;10 (suppl 2):S106-S115.
9. Bottomley A, Jones D, Claassens L. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency. Eur J Cancer. 2009;45:347-353.
10. Acquadro C, Berzon R, Dubois D, et al. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health. 2003;6:522-531.
11. Hüebner C, Petermann I, Browning BL, et al. Triallelic single nucleotide polymorphisms and genotyping error in genetic epidemiology studies: MDR1 (ABCB1) G2677/T/A as an example. Cancer Epidemiol Biomarkers Prev. 2007;16:1185-1192.
12. Bogardus ST Jr, Concato J, Feinstein AR. Clinical epidemiological quality in molecular genetic research: the need for methodological standards. JAMA. 1999;281:1919-1926.
13. Sprangers MAG, Sloan JA, Veenhoven R, et al. The establishment of the GENEQOL Consortium to investigate the genetic disposition of patient-reported quality-of-life outcomes. Twin Res Hum Genet. 2009;12:301-311.
14. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov. 2007;6:287-293.
15. Rosenberger WF, Sverdlov O. Handling covariates in the design of clinical trials. Stat Sci. 2008;23:404-419.
16. Mahajan R, Gupta K. Adaptive design clinical trials: methodology, challenges and prospect. Indian J Pharmacol. 2010;42:201-207.
17. Marko NF, Weil RJ. Mathematical modeling of molecular data in translational medicine: theoretical considerations. Sci Transl Med. 2010 Nov 3;2(56):56rv4.
18. Little RJA, Rubin DB. Statistical Analysis with Missing Data. 2nd ed. Hoboken, NJ: John Wiley and Sons; 2002.
19. Pujol A, Mosca R, Farrés J, Aloy P. Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci. 2010;31:115-123.
20. Wang R, Lagakos SW, Ware JH, et al. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357:2189-2194.
21. Fayers PM, Machin D. Quality of Life: The Assessment, Analysis and Interpretation of Patientreported Outcomes. 2nd ed. Chichester, England: John Wiley & Sons; 2007.
22. Fairclough DL. Design and Analysis of Quality of Life Studies in Clinical Trials. 2nd ed. Boca Raton, FL: Chapman & Hall/CRC; 2010.
23. Donaldson GW, Moinpour CM. Individual differences in quality-of-life treatment response. Med Care. 2002;40(6 suppl):III-39-III-53.
24. Hambleton RK, Swaminathan H, Rogers HJ. Fundamentals of Item Response Theory. Newbury Park, CA: Sage Publications; 1991.
25. Cella D, Gershon RC, Lai JS, Choi S. The future of outcomes measurement: item banking, tailored short-forms, and computerized adaptive assessment. Qual Life Res. 2007;16(suppl 1):133-141.
26. Panel on Handling Missing Data in Clinical Trials, National Research Council. The Prevention and Treatment of Missing Data in Clinical Trials. Washington, DC: National Academies Press; 2010.
27. Marquis P, Chassany O, Abetz L. A comprehensive strategy for the interpretation of qualityof- life data based on existing methods. Value Health. 2004;7:93-104.
28. McLeod LD, Coon CD, Martin SA, et al. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11:163-169.
29. Hays RD, Brodsky M, Francis M, et al. Evaluating the statistical significance of health-related quality-of-life change in individual patients. Eval Health Prof. 2005;28:160-171.
30. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995;273:59-65.
31. Kent DM, Rothwell PM, Ioannidis JP, et al. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials. 2010;11:85.
32. Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA. 2007;298:1209-1212.
33. Dmitrienko A, Tamhane A, Bretz F, eds. Multiple Testing Problems in Pharmaceutical Statistics. Boca Raton, FL: Chapman & Hall/CRC; 2009.
34. Donaldson G. Patient-reported outcomes and the mandate of measurement. Qual Life Res. 2008;7:1303-1313.
35. Mayo MS, Gajewski BJ, Morris JS. Some statistical issues in microarray gene expression data. Radiat Res. 2006;165:745-748.
36. US Food and Drug Administration. Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Federal Register. 2009;74:65132-65133.
37. US Food and Drug Administration. Building the infrastructure to drive and support personalized medicine. www.fda.gov/AboutFDA/ReportsManualsForms/Reports/ucm274440.htm. Accessed July 25, 2012.